Alvotech
Status: Publicly traded
Direct answer
Alvotech is publicly traded on NASDAQ under the ticker ALVO.
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of...
Can you invest in Alvotech?
Yes. Alvotech trades publicly on NASDAQ as ALVO.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Detailed equity research is provided by MarketSnap.